Lorals (anti-infection lingerie)

History

2022: Product Announcement

In May 2022, Lorals ultra-thin underwear, designed to prevent sexually transmitted infections (STIs) during oral sex, entered the market. The US Food and Drug Administration (FDA) has granted the manufacturer permission to sell the product on the US market. Lorals was the first product with such a certificate.

On dannymthe the New York Times, the company from Los Angeles got permission of FDA in May 12, 2022, approximately in four years after it was based by the current CEO Melanie Kristol. The brand offers an assortment of underwear made of "ultra-thin, silky-smooth" latex. According to the Lorals website, the products are designed to provide the desired sensations for oral sex without skin-to-skin contact, effectively reducing the risk of infection with sexually transmitted diseases and harmful pathogens.

Lorals did not have to conduct its own clinical trials; however, in order to obtain FDA approval, the Lorals team had to prove that their products are as effective as dental fillings - the only FDA-authorized product representing a thin rubber sheet that provides a barrier between the mouth and genitals during oral sex, Kristol said.

{{quote 'We had to meet physical requirements such as size, thickness, elasticity, strength and absence of holes, "Kristall told the publication. Then the product had to be checked for compatibility with the human body. Therefore, we conducted tests for toxicity, irritation and sensitization. }} Lorals linen can be purchased in packages of four pieces at a price of $25. Disposable briefs have a vanilla aroma and are elastic enough to suit a wide range of body types. The availability of the product outside the United States by mid-May 2022 is not reported.^[1]

Notes